Clinical Trial

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Name: Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma — clinical trial record (NCT06845241)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed or refractory non-hodgkin lymphoma.

Trial Details

NCT Number	NCT06845241
Lead Sponsor	Beijing InnoCare Pharma Tech Co., Ltd.
Conditions	Relapsed or Refractory Non-Hodgkin Lymphoma
Enrollment	68 participants
Start Date	2025-02
Primary Completion	2028-07 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2025-02-25